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Abstract
Background Pruritus is still a forgotten aspect of
hidradenitis suppurativa (HS) and, to date, has never been
adequately studied.
Objective The aim of this study was to determine the
prevalence, and explore the characteristics, of pruritus in a
well-defined cohort of HS patients.
Setting An academic hospital-based cross-sectional study
in The Netherlands.
Methods A numerical rating scale (NRS, 0–10) was used
to determine the prevalence of HS-related itch (NRS score
C3). Candidate predictors for pruritus were subsequently
determined using logistic regression models, and the
impact of pruritus was assessed using a modified five-di-
mensional (5-D) itch scale. Associated serological and
histological markers of pruritus were (semi-)quantitatively
investigated in a subpopulation.
Results The prevalence rate of pruritus in 211 HS patients
was 57.3%, with a mean NRS score of 6.1 ± 2.0. Patients
with a pruritus NRS score C3 had more HS-affected body
sites than patients with a score \3 (p\ 0.001). The
occurrence of a pruritus NRS score C3 was associated with
Hurley III disease (odds ratio [OR] 7.73; p = 0.003) and
pain (OR 1.34; p\ 0.001). Pruritus affected sleep and
activities of daily living (ADL) in the majority of cases,
with an associated modified 5-D itch score of 13.7 ± 3.6
(on a scale from 5 to 25) in 52 HS patients. Histological
examination showed eosinophilic granulocytes were pre-
sent in 25% (2/8) of the perilesional skin and 63% (10/16)
of the lesional skin, while a perineural infiltrate was found
in 25% (2/8) and 69% (11/16) of the perilesional and
lesional skin, respectively.
Conclusion Pruritus is a frequent but underreported
symptom in patients with HS. Its moderate to severe
intensity and significant impact on daily activities have
great potential to impair patients’ quality of life.
Key Points
Pruritus or itch is a frequent and bothersome
symptom in hidradenitis suppurativa (HS).
The presence of eosinophilic granulocytes and a
perineural infiltrate in lesional skin might explain the
reason for pruritus in HS.
The assessment of itch in both daily practice and
clinical research settings may form a helpful
additional patient-reported outcome measure to
evaluate the disease activity/severity of HS.
1 Introduction
Hidradenitis suppurativa (HS), also known as acne inversa,
is a chronic, recurrent, inflammatory skin disease that
mostly develops after puberty and predominantly occurs in
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women, with a female-to-male ratio of 3:1 [1, 2]. The
estimated prevalence rate in Europe is approximately 1%
[1]. Risk factors for developing HS are smoking and
overweight or obesity [3]. The disease is characterized by
deep-seated, inflamed nodules and abscesses, often fol-
lowed by sinus tract formation, and is most commonly
located in the flexural body sites carrying terminal hairs
[4].
Key symptoms of HS include acute and chronic pain,
discomfort, and a purulent, foul-smelling discharge, which,
overall, contribute to a poor quality of life [5, 6]. Previous
clinical studies have mainly focused on these well-known
symptoms [1, 4, 5], while less is known about the itch
sensation, also known as pruritus. In 2011, a small quali-
tative study in which 12 HS patients were interviewed for
the first time revealed that not only drainage, pain, and
scarring but also itching have a significant psychosocial
impact in HS patients [7].
To date, one cross-sectional study demonstrated a pos-
itive association between disutility and itch in a cohort of
294 HS patients, using the EuroQoL-5D (EQ-5D) and a
visual analog scale (VAS), respectively [8]. However, the
prevalence and accompanying (psychosocial) factors of
pruritus in HS have not been adequately investigated to
date. The aim of this study was to determine the preva-
lence, and explore the characteristics, of pruritus in a
cohort of HS patients. In addition, serological and histo-
logical markers of pruritus were evaluated in a
subpopulation.
2 Materials and Methods
2.1 Study Design and Population
This cross-sectional study consisted of consecutive male
and female patients with a physician-verified diagnosis of
HS who visited the Department of Dermatology, Erasmus
University Medical Center, Rotterdam, The Netherlands.
Each patient filled out a questionnaire relating to the
intensity of pruritus and the pain caused by their HS.
Patients with a limited understanding of the Dutch lan-
guage, as well as patients with a concomitant skin disease
that might cause pruritus (e.g. psoriasis, atopic dermatitis,
chronic urticaria) were excluded.
2.2 Epidemiological and Clinical Parameters
Patients separately assessed the highest intensity of their
pruritus and pain over the past 7 days on an 11-point
numerical rating scale (NRS) ranging from 0 (no itch/pain)
to 10 (unbearable/extreme itch/pain) [9]. All patients with
an NRS score C3 were included in the prevalence analysis.
It has previously been demonstrated that the minimal
clinically important difference (MCID) for clinical
improvement in itch ranks as a decrease of 2.7 points rated
on the NRS in the last 3 days [10].
Clinical parameters were collected during routine care
and were derived from medical charts. HS severity was
assessed using the Hurley classification of the worst
affected body area [11], and the extent of disease activity
was evaluated by the number of anatomical skin regions
with inflammation. The presence of three or more
papules/pustules, one or more inflammatory nodules, one
or more draining sinuses, or one or more abscesses per
region (left and right separate) was considered as inflam-
matory active HS disease. Additionally, the NRS relating
to pain was used as the patient-reported outcome measure
(PROM) of disease activity.
2.3 The Impact of Pruritus
Randomly selected patients with a pruritus NRS score
C3 were asked to fill in a five-dimensional (5-D) itch
scale, which is used to evaluate the impact of pruritus on
daily activities and includes five domains—duration,
degree, direction, disability, and distribution [12].The
questionnaire was adapted through (1) translation into
Dutch, and (2) explicitly mentioning the axillary and
genital regions, with removal (i.e. points of contact with
clothing) and merging (i.e. tops of feet and soles; palms
and tops of hands; thighs and lower legs; forearms and
upper arms) of non-relevant sections in the distribution
domain. The latter was carried out to obtain better
insight into the HS predilection areas, and resulted in 12,
instead of 16, answer options (electronic supplementary
material 1). The outcomes of domains 1–4 are measured
on a 5-point Likert scale [12]. The scoring system for
the distribution domain was not adapted as it was not
expected that HS patients without concomitant skin dis-
ease that might cause pruritus would have more than 12
skin regions with symptoms of itch. The overall 5-D
score was calculated by adding up the individual scores
of the five domains, resulting in scores ranging from 5
(no impact) to 25 (most severe impact on daily life)
[12].
2.4 Serological Analysis
A random subset of HS patients aged C18 years with a
pruritus NRS score C3 was asked for a one-time collec-
tion of a blood sample in order to screen for other pos-
sible causes of pruritus [13, 14].Tryptase, hemoglobin,
bilirubin, creatinine, urea, thyroid-stimulating hormone
(TSH), and glycated hemoglobin (HbA1c) were assessed
in serum.
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2.5 Histological Analysis
Histopathological analysis was performed on 24 random
HS skin samples (including eight perilesional skin samples,
and six early and ten chronic lesions) in order to evaluate
potential skin-related mediators of pruritus. Large speci-
mens of chronic inflamed skin were obtained from the
excised skin of patients who had radical excision of their
HS under general anesthesia as this was considered waste
material. In our clinic, HS lesions are excised with a
healthy-appearing skin margin of 2 cm; this normal-ap-
pearing skin is denoted as perilesional skin. All early (i.e.
newly emerging) HS lesions, as judged by both the HS
patient and the dermatologist, were biopsied within 4 days
after onset.
Three independent observers (ARJVV, KRvS, and EPP),
blinded to the disease stage, assessed all skin samples,
stained by hematoxylin and eosin (H&E), on the density of
the infiltrate, followed by evaluation of eosinophilic gran-
ulocytes and perineural involvement within the infiltrate.
The outcomes were scored in a semiquantitative manner
using a global assessment on an ordinal scale from 0 to 3
(0 = none, 1 = mild, 2 = moderate, 3 = severe) [15].
Disagreements between the three observers were resolved
through discussion until consensus was reached. The
average overall score per category was calculated from the
consensus score of the observers.
2.6 Statistical Analysis
Statistical analyses were conducted using SPSS Statistics
21.0 (IBM Corporation, Armonk, NY, USA). Patient
characteristics were analyzed using descriptive statistics,
with continuous data presented as the mean ± standard
deviation (SD) or mean and interquartile range (IQR),
and categorical data presented as number (%). A Shapiro–
Wilk test was performed to test whether continuous data
were normally distributed. For the primary objective, i.e.
the evaluation of patient characteristics between patients
with and without pruritus, the parametric t test for normally
distributed independent samples (two-sided), the non-
parametric Mann–Whitney U test for non-normally dis-
tributed samples, and the Chi-square test or Fisher’s exact
test for categorical data were applied. Candidate predictors
for pruritus, based on both clinical experience and the lit-
erature, were subsequently determined using both uni-
variable and multivariable logistic regression models, with
pruritus (NRS score C3) as the dependent variable. In order
to prevent overfitting of the regression analysis, we were
restricted to using 9 degrees of freedom in the multivariate
model, as the limiting sample size of patients without
pruritus was 90 (Table 1) [15]. Data were presented as
odds ratio (OR) with 95% confidence intervals (CIs). In all
comparisons, a two-sided p value of 0.05 was considered
significant.
2.7 Ethical Statement
The Medical Ethical Committee of the Erasmus University
Medical Center, Rotterdam, The Netherlands, reviewed
and approved the study protocol (reference MEC-2016-
092). Written informed consent for the serological and
histological analysis was obtained from all subjects in
accordance with the Declaration of Helsinki principles.
3 Results
3.1 Epidemiology of Pruritus
A total of 231 HS patients were screened, of whom 20 were
excluded (13 had a concomitant dermatological comor-
bidity causing itch, 5 had a limited understanding of the
Dutch language, and 2 patients declined to take part in the
study). The 211 patients included in the study (64%
female) had a median age of 38 years (range 15–71)
(Table 1). The prevalence rate (NRS score C3) of pruritus
was 57.3% (121/211), with a mean NRS score of
6.1 ± 2.0. For comparison, applying a cut-off value of an
NRS score C1 resulted in a rate of 67.3% (mean NRS score
of 5.4 ± 2.5). The mean intensity of itch in all 211 patients
was rated at an NRS score of 3.7 ± 3.3. The occurrence of
pain (NRS score C3) was more frequently reported,
resulting in a prevalence rate of 83.4% and associated
mean NRS score of 7.4 ± 1.8.
3.2 Patient Characteristics
Comparison of the patient characteristics between patients
with pruritus (NRS score C3) and patients reporting no or
negligible pruritus (NRS score\3) revealed no significant
differences, with the exception of HS disease activ-
ity/severity (Table 1). Patients with a pruritus NRS score
C3 reported a higher level of pain (p\ 0.001), had more
affected body areas (p\ 0.001), and had more severe
disease according to the Hurley classification (p\ 0.001)
compared with patients reporting a pruritus NRS score\3
(Table 1). Candidate predictors for patients reporting a
pruritus NRS score C3 were Hurley stage III (OR 7.73;
p = 0.003) and pain, with an OR of 1.34 for each addi-
tional point on the NRS (p\ 0.001) (Table 2). A higher
number of currently inflamed areas was only associated
with pruritus in the univariable analysis (OR 1.70;
p\ 0.001). In addition, patients who smoked tended to
complain more about itch than patients who have never
smoked (univariable analysis; OR 2.27; p = 0.03).
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3.3 The Impact of Pruritus
Fifty-two patients in the pruritus NRS score C3 group
(n = 121) completed the 5-D itch scale; however, one
incorrectly filled out questionnaire was excluded from the
analysis. First, the most commonly reported pruritus
characterization was moderate (54%) to severe (27%)
itching sensations for less than 6 h per day (56%), which
had not changed in the previous 2 weeks (48%). Second,
pruritus, at least occasionally, affected sleep and activities
of daily living (ADL), i.e. leisure, social contact, house-
work, errands, and work/school, in 70 and 53% of patients,
respectively (Fig. 1a). The mean number of body areas
affected by pruritus was 3.1 ± 2.5, with the inguinal/gen-
ital (67%) and axillary (52%) regions most frequently
involved (Fig. 1b). The overall modified 5-D itch score was
13.7 ± 3.6, i.e. HS-related pruritus had a moderate impact
on daily activities.
Table 1 Patient characteristics
Total [n = 211] Pruritus NRS score C3 [n = 121] Pruritus NRS score\3 [n = 90] p value
Age, years 38.0 (29–49) 38.0 (29–48) 39.0 (29–52) 0.39
Female sex 135 (64) 78 (65) 57 (63) 0.87
BMI, kg/m2 28.5 ± 5.9 28.7 ± 5.8a 28.3 ± 6.0b 0.67
Diabetes mellitus 18 (9) 10 (8) 8 (9) 0.87
Smoking statusc 0.05
Never smoked 37 (20) 16 (13) 21 (23)
Present smoker 42 (62) 83 (70) 48 (54)
Past smoker 131 (18) 21 (18) 21 (23)
Pack-yearsd 12.0 (7–23) 12.9 (6–22) 12.0 (7–26) 0.65
Positive family historye 80 (38) 49 (41) 31 (34) 0.37
Use of systemic medication 64 (32) 36 (30) 28 (31) 0.92
Skin type (Fitzpatrick)f 0.49
I 18 (9) 14 (12) 4 (5)
II 126 (60) 69 (57) 57 (63)
III 17 (8) 11 (9) 6 (7)
IV 30 (14) 17 (14) 13 (14)
V 11 (5) 5 (4) 6 (7)
VI 9 (4) 5 (4) 4 (4)
Duration of HS, years 14.0 (7–25) 15.0 (8–27) 13.0 (5–23) 0.22
HS severityg \0.001**
Hurley I 32 (15) 13 (11) 19 (21)
Hurley II 140 (66) 75 (62) 65 (72)
Hurley III 39 (19) 33 (27) 6 (7)
Currently inflamed areash 1.5 ± 1.3 1.7 ± 1.4 0.9 ± 1.1 \0.001**
Pain on NRS 6.3 ± 3.0 6.9 ± 2.5 5.0 ± 3.5 \0.001**
Data are expressed as mean ± SD, median (IQR), or n (%)
BMI body mass index, HS hidradenitis suppurativa, IQR interquartile range, NRS numerical rating scale, SD standard deviation
* Indicates significant at p = 0.05, ** indicates significant at p = 0.001
a Missing n = 6
b Missing n = 9
c Missing n = 1
d Pack-year = (number of cigarettes smoked per day 9 number of years smoked)/20
e A positive family history for HS symptoms in first- and second-degree relatives
f Fisher’s exact test
g Chi-square test
h Inflamed area = three or more papules/pustules, one or more inflammatory nodules, one or more draining sinuses, or one or more abscesses
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3.4 Serological Analysis
Serum pruritus markers were evaluated in 24 patients in the
pruritus NRS score C3 group (n = 121). The mean com-
mon serum values were within the normal range, with the
exception of a lower hemoglobin level found in male
patients (n = 5) (Table 3). Three outliers were detected:
tryptase (19.3 lgr/L) in one patient with a pruritus NRS
score of 7, and HbA1c (91.0 and 57.0 mmol/mol) in two
patients with pruritus NRS scores of 3 and 5, respectively.
3.5 Histological Analysis
The average semiquantitative scores for the three types of
HS skin specimens are presented in Fig. 2. Histological
evaluation showed that inflammatory cell infiltration was
present (i.e. score of 1–3) in 75% (6/8) of the perilesional
samples, and 100% (16/16) of both early and chronic
lesional samples. Eosinophilic granulocytes were present
(i.e. score of 1–3) in 25% (2/8) of perilesional skin and
63% (10/16) of lesional skin (Fig. 3a). A perineural infil-
trate, mainly consisting of lymphocytes and a few
neutrophils, was found in 25% (2/8) and 69% (11/16) of
perilesional and lesional skin, respectively (Fig. 3b).
4 Discussion
For the first time, this explorative study evaluated the
prevalence and clinical characteristics of pruritus in a well-
defined cohort of HS patients. We demonstrated a high
prevalence rate of 57% (121/211 with an NRS score C3),
with a mean NRS score of 6.1 ± 2.0. This prevalence rate
is substantially higher than the prevalence of itch in a
healthy French population (29%) and a Norwegian national
sample with several ethnicities (7%) [16, 17]. A recently
conducted study involving a general dermatological pop-
ulation of a German clinical practice reported a 36%
prevalence rate of itch [18]. Compared with other inflam-
matory skin conditions, the 57% prevalence rate of pruritus
in HS is similar to the rate in patients with psoriasis
(49–90%) [18, 19], and lower than patients with burn
injuries (67–93%) [20, 21] or chronic idiopathic urticaria
(79%) [22].
Table 2 Associations between
patient characteristics and the
occurrence of itch in 211 HS
patients
Coding Univariablea Multivariablea
OR (95% CI) p value OR (95% CI) p value
Age
Continuous 0.99 (0.97–1.01) 0.33 0.97 (0.94–1.01) 0.10
Sex
Male 1.05 (0.60–1.86) 0.87 0.75 (0.37–1.53) 0.75
Smoking status
Never smoked Reference variable Reference variable
Present smoker 2.27 (1.08–1.76) 0.03* 2.02 (0.82–4.95) 0.13
Past smoker 1.31 (0.54–3.19) 0.55 1.26 (0.43–3.68) 0.67
Duration of HS (years)
Continuous 1.02 (0.99–1.04) 0.20 1.04 (1.00–1.07) 0.38
HS severity
Hurley I Reference variable Reference variable
Hurley II 1.69 (0.77–3.68) 0.19 1.78 (0.72–4.45) 0.22
Hurley III 8.04 (2.62–25) \0.001** 7.73 (2.01–27) 0.003*
Currently inflamed areas
Continuous 1.70 (1.32–2.19) \0.001** 1.21 (0.92–1.58) 0.18
Pain on NRS
Continuous 1.35 (1.12–1.50) \0.001** 1.34 (1.18–1.52) \0.001**
HS hidradenitis suppurativa, NRS numerical rating scale, OR odds ratio, CI confidence interval
* Indicates significant at p = 0.05, ** indicates significant at p = 0.001
a Logistic regression analysis with a pruritus NRS score C3 as the dependent variable: univariable model,
unadjusted; and multivariable model, adjusted for factors and covariates in the model (OR[1 is a predictor
for the occurrence of itch)
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The overall mean intensity of itch in this study (NRS
score 3.7 ± 3.3) was similar to the pruritus VAS score of
3.7 ± 3.2 in a cohort of 294 HS patients [8]. In addition,
the mean modified 5-D itch score of 13.7 ± 3.6 in 52 HS
patients is comparable with the 5-D score in 51 patients
with an inflammatory skin condition such as burn wounds
(13.5 ± 3.2) [12]. Systemic diseases such as HIV/AIDS
(n = 28; 16.8 ± 5.3), chronic liver disease (n = 63;
16.9 ± 4.7), and chronic kidney disease (n = 36;
18.2 ± 4.1) have shown higher 5-D itch scores [12];
however, the majority (81%) of HS patients ranked the
severity of pruritus as moderate to severe on a 5-point
Likert scale. Moreover, sleep and ADL were negatively
impacted by pruritus in more than half of the patients.
Pruritus is a multidimensional phenomenon and is
thought to signal danger from various environmental fac-
tors or physiological abnormalities. Therefore, it frequently
accompanies various inflammatory skin conditions,
including atopic dermatitis, psoriasis, chronic urticaria, and
burn wound healing [23].To date, the etiology of pruritus in
skin diseases is only partially understood. A possible
explanation for itching in HS patients is the presence of
tryptase-positive mast cells, which were found to be
increased in all stages of the disease, including perilesional
skin [24]. Increased serum levels of immunoglobulin (Ig)E
have recently been reported in patients with HS. The latter,
in combination with a dense infiltration of mast cells in HS,
could trigger degranulation of these cells, releasing
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Fig. 1 The Modified
5-Dimensional Itch Scale of 52
hidradenitis suppurativa patients
with a pruritus numerical rating
scale score of C3. (a) Disability:
the impact of itch on sleep and
ADL in the past 2 weeks.
(b) Distribution of itch per body
area in the past 2 weeks. ADL
activities of daily living, based
on the highest outcome of the
three subcategories in the
questionnaire
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histamine and other mediators, such as proteases, causing
pruritus [25]. In addition, we found an influx of eosino-
philic granulocytes and the presence of a perineural infil-
trate (when nerve fibers were present) in the majority of
prototypic HS lesions. An important phenomenon sup-
porting the hypothesis of neurogenic inflammation is the
finding of an abnormal innervation of the skin in psoriasis
[26]. As demonstrated in cutaneous T-cell lymphoma,
interleukin (IL)-31 may play a role by exerting indirect
effects on sensory nerves through keratinocytes to transmit
itch signals [27]. However, itch in HS patients could also
result from a small fiber neuropathy due to scar formation
in the course of HS. Recurrent and chronic inflammation
will destroy dermal nerves and subsequently enhance nerve
regeneration and neovascularization when inflammation
has subsided. This type of neuropathic itch coincides with
pain and may be caused by a disproportionate number of
regenerating, unmyelinated C nerve fibers within HS
lesions [28].
The major strength of this explorative cross-sectional
study is the recruitment of a relatively large number of
physician-verified HS patients. As the occurrence of
itch at a specific point in time is susceptible to con-
founders such as mental distress, use of systemic
medication, and comorbidities [29], a comparator group
and quality-of-life measurements, e.g. Dermatology
Quality of Life Index (DLQI) or SKINDEX-29, are
indicated for future research. Another strength is
screening for common systemic causes of chronic
recurrent itch that could interfere with the occurrence of
HS-related itch. In addition, histopathological evalua-
tion of two important skin-related mediators of pruritus
have been performed, although the evaluation lacks
information relating to the associated presence of pru-
ritus. For future analysis, it would be interesting to
evaluate specific itch-related biomarkers in the serum or
skin lesions, such as eosinophilic granulocytes, thymus
and activation-regulated chemokine (TARC), IL-2, IL-
31, and substance P.
A limitation of this study could be the use of a non-
validated, HS-modified 5-D itch scale. From a clinical
point of view, the alteration of the distribution section was
not expected to influence scoring as HS patients rarely have
notable itch in distal, unaffected body sites such as the
hands and feet. Moreover, the body areas mentioned in the
distribution domain of the adapted scale are more specific
to HS-related itch (electronic supplementary material 1).
The modified 5-D itch scale, which could be validated for
this application in future research, could therefore be a
specialized and very useful tool for analysing pruritus in
HS patients.
5 Conclusion
Pruritus is a frequent but underreported aspect of HS. Its
moderate to severe intensity and significant impact on
sleep and ADL have great potential to impair patients’
quality of life. Therefore, assessment of pruritus in both
daily practice and clinical research settings, e.g. by using
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Fig. 2 Semiquantitative scores
for histological markers of
pruritus in three types of
hidradenitis suppurativa lesions.
A total of 24 samples were
assessed: perilesional, n = 8;
early lesional, n = 6; chronic
lesional, n = 10. The y-axis
indicates the average
semiquantitative scores on an
ordinal scale from 0 to 3
(0 = none, 1 = mild,
2 = moderate, 3 = severe)
Table 3 Serum pruritus markers of 24 hidradenitis suppurativa
patients with itch
Serum pruritus marker Units Mean value Reference
Bilirubin lmol/L 6.0 ± 2.6 \17
Creatinine lmol/L 69.4 ± 16.8 55–115a
HbA1cb mmol/mol 38.9 ± 12.7 26–42
Hemoglobin
Men (n = 5) mmol/L 8.4 ± 1.2 8.6–10.5
Women (n = 19) mmol/L 8.4 ± 0.6 7.5–9.5
Tryptase lgr/L 5.4 ± 3.5 \11.4
TSH mU/L 1.6 ± 1.0 0.4–4.3
Ureab mmol/L 4.0 ± 1.5 2.5–7.5
HbA1c glycated hemoglobin, TSH thyroid-stimulating hormone
a Upper limit dependent on ethnic origin, sex and age
b n = 1 missing
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an NRS or VAS, together with the DLQI and EQ-5D,
may form a helpful additional PROM to evaluate disease
severity/activity and treatment outcome.
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